Back to top
more

BioCardia (BCDA)

(Real Time Quote from BATS)

$2.37 USD

2.37
28,636

-0.02 (-0.84%)

Updated Nov 4, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -258.23% and 93.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 7.93%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

MiMedx (MDXG) delivered earnings and revenue surprises of 40% and 3.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include TAL Education Group (TAL), BioCardia (BCDA), Angi (ANGI), Xcel Energy (XEL) and SoFi Technologies (SOFI).

BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study

by Zacks Equity Research

The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.

BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

BioCardia (BCDA) Up on Plans for Second Heart Failure Study

by Zacks Equity Research

BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.

BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

by Zacks Equity Research

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.

BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -13.33% and 87.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -5.88% and 21.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -26.83% and 62.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 26.98% and 3.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.

BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -26.67% and 68.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Will High Costs & Low Sales Dent Braskem (BAK) Q1 Earnings?

by Zacks Equity Research

Braskem's (BAK) upward cost trajectory is likely to have continued in the first quarter due to higher feedstock prices in international markets and global supply chain constraints.

Ovintiv (OVV) Q1 Earnings Coming Up: Here's How It Will Fare

by Zacks Equity Research

Ovintiv's (OVV) first-quarter earnings are expected to have benefited from the surge in oil and natural gas prices.

Will Suncor (SU) Reverse the Previous Miss in Q1 Earnings?

by Zacks Equity Research

Suncor Energy (SU) is expected to have benefited from the surge in oil realizations.

BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

by Zacks Equity Research

BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

    Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.63% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?